By Darrin LaVelle, Founder of RENVA Health
Last updated: July 4, 2026
Short answer: every FDA-approved GLP-1 medication starts at a low dose and increases on a fixed schedule — typically every 4 weeks — specifically to reduce side effects while working toward an effective maintenance dose. This schedule isn't arbitrary; it's the exact regimen tested in clinical trials, and deviating from it (in either direction) isn't something clinical trial data actually supports.
If you're starting a GLP-1 medication, understanding the titration schedule you'll actually be following — and why it's structured the way it is — helps set realistic expectations for the first several months of treatment. Here's what the approved schedules look like, why they matter, and a consumer-protection issue worth knowing about: "microdosing" programs that deviate from these tested schedules.
A note before diving in: the specific schedules below reflect FDA labeling for reference and general understanding. Your actual prescribed schedule should always come from your own prescriber, who may adjust timing based on your individual tolerance — this article isn't a substitute for those specific instructions.
Starting any of these medications at their full effective dose would produce a much higher rate of nausea, vomiting, and other gastrointestinal side effects than most people could reasonably tolerate. Gradual dose escalation gives the digestive system and appetite-regulating pathways time to adjust at each step before moving to the next, which is the entire reason these schedules exist — they're a built-in safety and tolerability feature, not a delay tactic.
Wegovy comes in six dose strengths, and the FDA-approved schedule increases roughly every 4 weeks:
| Weeks | Dose |
|---|---|
| 1–4 | 0.25 mg weekly |
| 5–8 | 0.5 mg weekly |
| 9–12 | 1.0 mg weekly |
| 13–16 | 1.7 mg weekly |
| 17+ | 2.4 mg weekly (maintenance) |
A higher-dose option, Wegovy HD (7.2 mg weekly), is available for additional weight loss beyond the standard maintenance dose, following its own escalation from the 2.4 mg level. If a dose isn't well tolerated, labeling allows for delaying the next increase or stepping back to the previous tolerated dose rather than pushing forward on schedule regardless of symptoms.
Zepbound follows a similar 4-week-per-step pattern across six dose levels:
| Step | Dose |
|---|---|
| 1 | 2.5 mg weekly (first 4 weeks) |
| 2 | 5 mg weekly |
| 3 | 7.5 mg weekly |
| 4 | 10 mg weekly |
| 5 | 12.5 mg weekly |
| 6 | 15 mg weekly (maximum) |
As with Wegovy, labeling explicitly allows for using a lower maintenance dose than the maximum if that's what someone tolerates best — reaching the highest dose isn't a requirement for everyone.
Since Foundayo is a daily pill rather than a weekly injection, its schedule is structured differently, with each step held for a longer period — a full 30 days minimum per level, specifically to minimize GI side effects:
| Weeks | Dose |
|---|---|
| 0–4 | 0.8 mg daily |
| 5–8 | 2.5 mg daily |
| 9–12 | 5.5 mg daily |
| 13+ | Up to 9 mg daily |
| 17+ | Up to 14.5 mg daily |
| 21+ | Up to 17.2 mg daily (maximum) |
Foundayo's labeling specifically emphasizes not shortening the 30-day interval at each dose level — this isn't a flexible suggestion but a specific instruction built into how the drug was tested.
The oral tablet version of Wegovy follows the same underlying logic as the injectable version — starting at a lower tablet strength and increasing in steps toward the 25 mg daily maintenance dose over several weeks. As with every other option here, prescribers are instructed not to skip steps or start a treatment-naive patient directly at the maintenance dose.
This isn't just about comfort during the first few months — there are real safety reasons the schedule exists and is worth respecting in both directions.
Going faster than prescribedincreases the risk of severe gastrointestinal side effects, which can in turn lead to dehydration and, in some cases, acute kidney injury from fluid loss. The FDA has been specific about this risk in the context of compounded products: in its 2026 statement on unapproved GLP-1 drugs, the agency noted it had received reports of adverse events requiring medical attention specifically tied to patients receiving compounded products at doses beyond what's specified on the approved label. The symptoms cited — nausea, vomiting, diarrhea, abdominal pain, and constipation — are a direct, documented consequence of dosing that outpaces what a person's body has had time to adjust to.
Going slower or lower than testedisn't necessarily dangerous, but it hasn't been evaluated in the same clinical trials that established these medications' safety and effectiveness data. Any deviation from the tested regimen means you're outside the specific conditions that data was collected under.
Missed-dose guidance varies slightly by medication, and this is exactly the kind of detail worth confirming directly with your prescriber or pharmacist rather than guessing, but the general patterns from labeling are:
The common thread across all three: extended gaps in treatment generally mean restarting at a lower dose rather than picking back up where you left off, since your body may have lost some of the tolerance it built up during the original titration.
Separately from the standard titration schedules above, some telehealth and weight-loss programs have marketed what they call "microdosing" — prescribing GLP-1 medications (sometimes compounded versions) at doses well below standard titration steps, often framed with language like "a smaller dose, a smarter start."
This is worth understanding clearly: this approach deviates from FDA-approved titration schedules, and it hasn't been evaluated in randomized clinical trials for either effectiveness or long-term safety. It's a marketing framing, not a tested clinical protocol.
This came to a head in May 2026, when the National Advertising Division (NAD) — an advertising industry self-regulatory body, not the FDA — reviewed a challenge brought by Eli Lilly against Noom's "Microdose GLP-1Rx" program. NAD recommended that Noom modify or discontinue its claim that the program represented "a smaller dose, a smarter start," finding that Noom hadn't provided adequate evidence that the lower-dose approach delivered any measurable health benefit that would make it a genuinely "smarter" way to begin treatment.
It's worth being precise about what this case does and doesn't establish: NAD isn't a government regulator and doesn't have FDA's enforcement authority — its recommendations are part of an industry self-regulation system, not a legal ruling. But the case reflects a broader point echoed in FDA's own guidance: dosing and titration for these medications is expected to follow approved labeling, and alternative approaches — whether marketed as microdosing or anything else — don't carry the same tested safety and effectiveness data that the standard schedules do, regardless of how the marketing frames it.
If a provider is offering a dosing approach that departs meaningfully from the schedules outlined above — whether faster, slower, or branded as "micro" dosing — it's worth asking directly what evidence supports that specific approach, and whether it's an FDA-approved regimen or something the provider has designed independently. Neither answer automatically means walk away, but it's exactly the kind of question a transparent, quality-focused provider should be able to answer clearly.
Q: Can I skip ahead in the titration schedule if I'm not experiencing side effects?
This should be a decision made with your prescriber, not something to adjust on your own — the schedule reflects the tested regimen, and skipping ahead departs from that regardless of how you're currently feeling.
Q: Is it bad if I need to stay at a lower dose longer than the standard schedule?
No — every label explicitly allows for extending time at a given dose, or using a lower maintenance dose, based on individual tolerance. This is a normal, anticipated part of treatment, not a sign you're doing something wrong.
Q: What's actually wrong with "microdosing" if it reduces side effects?
The core issue is that it hasn't been tested in clinical trials, so there's no reliable data on whether it's actually as effective, or genuinely safer long-term, compared to standard dosing. Reduced side effects from a lower dose isn't surprising, but it doesn't tell you whether the approach still delivers meaningful treatment benefit.
Q: What should I do if I accidentally take too much?
Contact your prescriber or pharmacist promptly, and monitor for symptoms like severe nausea, vomiting, or abdominal pain. This is different from routine mild side effects during normal titration and is worth treating as something to report right away.
Q: Does a compounded product follow the same titration schedule as the brand-name version?
It should, if it's being dosed responsibly — but the FDA has specifically flagged cases of compounded products being dosed beyond approved-label amounts, so this is worth confirming directly rather than assuming.
See also: How Long Does It Take for GLP-1 Medications to Work? for what to expect during each phase of the titration ramp-up, and Compounded vs. Brand-Name GLP-1 for why compounded products and their dosing deserve extra scrutiny.
Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →
Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.
Take the free quizGLP-1 medications start affecting appetite within days, but meaningful weight loss builds over months. Here's the actual week-by-week timeline from clinical trial data.
A clear look at GLP-1 side effects — from common nausea to rare but serious risks — based on FDA labeling and adverse event data, plus what tends to help.
Compounded GLP-1 medications aren't FDA-approved and aren't reviewed for safety or quality before they're sold. Here's what that actually means and why the distinction matters.